Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Abstract Background: Dysregulated Notch signalling has been implicated in a variety of cancers. R is a potent and selective inhibitor of -secretase, a key enzyme in Notch signalling. Phase I data demonstrated R to be tolerable but PK profile revealed auto-induction with repeated dosing at high doses (Tolcher et al. ASCO 2010). The primary aim of this study is to determine the optimal regimen of R using alternative dosing …